L3VLUP
ProSign in

GSK · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GSKVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GSK
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterGSKVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 20221 holders, $19m25 holders, $18.1bn
Q3 202218 holders, $3.9bn22 holders, $18.4bn
Q4 202218 holders, $4.9bn28 holders, $18.4bn
Q1 202313 holders, $4.4bn26 holders, $21.4bn
Q2 202313 holders, $4.3bn27 holders, $24.7bn
Q3 202316 holders, $4.5bn33 holders, $24.3bn
Q4 202313 holders, $4.5bn32 holders, $28.6bn
Q1 202413 holders, $5.3bn31 holders, $29.8bn
Q2 202410 holders, $4.6bn29 holders, $33.4bn
Q3 202410 holders, $4.9bn27 holders, $33.5bn
Q4 202413 holders, $4.9bn26 holders, $28.5bn
Q1 202511 holders, $6.3bn21 holders, $35.4bn
Q2 202510 holders, $6.2bn21 holders, $32.3bn
Q3 202511 holders, $7.5bn22 holders, $25.9bn
Q4 202511 holders, $8.8bn26 holders, $31.8bn
Q1 20269 holders, $9.1bn25 holders, $31.8bn
Q2 202611 holders, $7.5bn26 holders, $34.6bn
GSK

GSK PLC

Holders
10
Reported value
$4.9bn
Buyers
6
Sellers
3

Breadth +3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GSK (5)

Acadian Asset Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Dodge & Cox, Quantbot Technologies LP

Only VRTX (22)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →